Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 3/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | MPO | P05164 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | BLM | P54132 | 1/20 | 0.64 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.64 |
| ▸ | ECE1 | P42892 | 7/20 | 0.64 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.64 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5583846 | 1.00 | ACE (0.69) | ACEKDM4EMEN1LMNAMPO | |
| SCHEMBL29414401 | 0.94 | ACE (0.62) | ACEKDM4EMEN1LMNAMPO | |
| SCHEMBL11855463 | 0.93 | ACE (0.72) | ACEKDM4EMEN1LMNAMPO | |
| SCHEMBL5612810 | 0.93 | ACE (0.72) | ACEKDM4EMEN1LMNAMPO | |
| SCHEMBL29701966 | 0.93 | ACE (0.72) | ACEKDM4EMEN1LMNAMPO | |
| SCHEMBL5583839 | 0.93 | ACE (0.72) | ACEKDM4EMEN1LMNAMPO | |
| SCHEMBL3359705 | 0.93 | ACE (0.72) | ACEKDM4EMEN1LMNAMPO | |
| SCHEMBL9596897 | 0.93 | ACE (0.72) | ACEKDM4EMEN1LMNAMPO | |
| SCHEMBL9596908 | 0.93 | ACE (0.72) | ACEKDM4EMEN1LMNAMPO | |
| SCHEMBL9869824 | 0.93 | ACE (0.72) | ACEKDM4EMEN1LMNAMPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250296971-A1 | GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS | 3B PHARMACEUTICALS GMBH (DE) | 2025-09-25 | — | — | US | claimed |
| CN-118632858-A | Gastric inhibitory peptide receptor ligands | 3B制药有限公司 | 2024-09-10 | — | — | CN | claimed |
| EP-4423110-A2 | GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS | 3B Pharmaceuticals GmbH (DE) | 2024-09-04 | — | — | EP | claimed |
| WO-2023072971-A2 | GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS | 3B PHARMACEUTICALS GMBH (DE) | 2023-05-04 | — | — | WO | claimed |
| US-20070207957-A1 | Composition For Accelerating Alcohol Metabolism Or Relieving Fatigue By Gluconeogenesis | KIRIN BEER KABUSHIKI KAISHA (JP) | 2007-09-06 | — | — | US | claimed |
| EP-1757289-A1 | COMPOSITION FOR ACCELERATION OF ALCOHOL METABOLISM OR RECUPERATION FROM FATIGUE THROUGH GLUCONEOGENESIS | KIRIN BEER KABUSHIKI KAISHA (JP) | 2007-02-28 | — | — | EP | claimed |
| EP-0122151-B1 | PRODUCTION OF PRIMARY OR SECONDARY ALCOHOL DERIVATIVES OF PHOSPHOLIPIDS BY THE ENZYMATIC TECHNIQUE | MEITO SANGYO KABUSHIKI KAISHA (JP) | 1989-02-15 | — | — | EP | claimed |
| US-4783402-A | Production of primary or secondary alcohol derivatives of phospholipids by the enzymatic technique | MEITO SANGYO KABUSHIKI KAISHA (JP) | 1988-11-08 | — | — | US | claimed |
| EP-0122151-A2 | Production of primary or secondary alcohol derivatives of phospholipids by the enzymatic technique | MEITO SANGYO KABUSHIKI KAISHA (JP) | 1984-10-17 | — | — | EP | claimed |
| EP-3604503-B1 | ADDITIVE FOR UNDIFFERENTIATION MAINTAINING MEDIUM | AJINOMOTO KK (JP) | 2026-03-18 | — | — | EP | disclosed |
| US-12578345-B2 | Single molecule peptide sequencing | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2026-03-17 | — | — | US | disclosed |
| US-20260027203-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | ALETA BIOTHERAPEUTICS INC (US) | 2026-01-29 | — | — | US | disclosed |
| US-12492422-B2 | Ex vivo protease activity detection for disease detection/diagnostic, staging, monitoring and treatment | Sunbird Bio, Inc. (US) | 2025-12-09 | — | — | US | disclosed |
| US-20250297300-A1 | DETECTION, STAGING, MONITORING AND TREATING A DISEASE OR A CONDITION | Sunbird Bio, Inc. | 2025-09-25 | — | — | US | disclosed |
| CN-107049859-A | A kind of gently moist mildy wash and preparation method thereof | 广东科玮生物技术股份有限公司 | 2017-08-18 | — | — | CN | disclosed |
| US-20070207957-A1 | Composition For Accelerating Alcohol Metabolism Or Relieving Fatigue By Gluconeogenesis | KIRIN BEER KABUSHIKI KAISHA (JP) | 2007-09-06 | — | — | US | disclosed |
| EP-1757289-A1 | COMPOSITION FOR ACCELERATION OF ALCOHOL METABOLISM OR RECUPERATION FROM FATIGUE THROUGH GLUCONEOGENESIS | KIRIN BEER KABUSHIKI KAISHA (JP) | 2007-02-28 | — | — | EP | disclosed |
| EP-0122151-B1 | PRODUCTION OF PRIMARY OR SECONDARY ALCOHOL DERIVATIVES OF PHOSPHOLIPIDS BY THE ENZYMATIC TECHNIQUE | MEITO SANGYO KABUSHIKI KAISHA (JP) | 1989-02-15 | — | — | EP | disclosed |
| US-4783402-A | Production of primary or secondary alcohol derivatives of phospholipids by the enzymatic technique | MEITO SANGYO KABUSHIKI KAISHA (JP) | 1988-11-08 | — | — | US | disclosed |
| EP-0122151-A2 | Production of primary or secondary alcohol derivatives of phospholipids by the enzymatic technique | MEITO SANGYO KABUSHIKI KAISHA (JP) | 1984-10-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250296971-A1 | GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS | GIPR, VIP, GRPR | ACE 3951/4885KDM4E 4464/4885MEN1 1139/4885 |
| US-12578345-B2 | Single molecule peptide sequencing | SET, PTMS, MICA | ACE 2836/4885KDM4E 3313/4885MEN1 728/4885 |
| US-20260027203-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | CD44, BCR, BAG6 | ACE 3896/4885KDM4E 2688/4885MEN1 947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.